INHERIT EGFR - Studying Germline EGFR Mutations
NCT01754025 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 121
Last updated 2025-11-25
Summary
Lung cancer is a common malignancy that is associated with cigarette smoking but can also affect individuals who never smoked. It is not well understood whether there are hereditary risk factors that influence the risk of lung cancer.
It has been recently found that a small number of families have an inherited (passed from parent to child) change in one of their genes that may contribute to an increased tendency to develop lung cancers, even in never smokers. In some lung cancer patients this gene, called "EGFR", contains a DNA change known as an "inherited EGFR mutation". Early data indicate that these inherited EGFR mutations may be associated with an increased risk of lung cancer.
So far, only a small number of families have been found to carry inherited EGFR mutations. For this reason the risk of lung cancer associated with inherited EGFR mutations is not well understood. Understanding the risk may help investigators find ways of detecting lung cancer sooner or reducing the risk of developing lung cancer.
It was recently discovered that lung cancer patients who are found to carry one rare EGFR mutation in their cancer cells, called "T790M", have an increased risk of carrying an inherited EGFR mutation in their normal cells as well. This represents a new strategy for finding individuals and families carrying inherited EGFR mutations.
This research study is designed to find cancer patients whose tumors have this EGFR mutation, T790M, to find out if they also have an inherited EGFR mutation. Subjects will not have to undergo a biopsy to participate in this research study. Investigators will collect a saliva specimen from patients with a T790M in their cancer to find out if they also have an inherited EGFR mutation.
Study participants found or known to carry an inherited EGFR mutation will have the option of offering their close relative the opportunity to also participate in this study. Close relatives can consider testing to see if they also carry the inherited mutation in their normal cells. Once investigators have identified individuals and relatives that carry inherited EGFR mutations in their genes, investigators will then try to understand the risk of lung cancer and other cancers. Individuals with inherited EGFR mutations will also have the opportunity to participate in future studies related to cancer and other diseases.
This study is being funded in part by the Conquer Cancer Foundation of ASCO and the Bonnie J. Addario Lung Cancer Foundation.
Conditions
Sponsors & Collaborators
-
Addario Lung Cancer Medical Institute
collaborator OTHER - lead OTHER
Principal Investigators
-
Jaclyn LoPiccolo, MD · Dana-Farber Cancer Institute
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-12-28
- Primary Completion
- 2018-11-07
- Completion
- 2029-12-31
Countries
- United States
Study Locations
More Related Trials
-
Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients
NCT04222335 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
EGFR Mutations on ctDNA in Patients With Advanced NSCLC
NCT02623257 ·Status: COMPLETED
-
Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis
NCT01776684 ·Status: UNKNOWN ·Phase: NA
-
Mutations in the Epidermal Growth Factor Receptor(EGFR) Gene in Non-Small Cell Lung Carcinoma (NSCLC) and the Relation to Response of Treatment With Erlotinib
NCT00815971 ·Status: UNKNOWN
-
Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung Cancer
NCT04742192 ·Status: COMPLETED
-
Acquired Resistant Mechanism of the First-generation EGFR TKIs
NCT02804217 ·Status: UNKNOWN
-
Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
NCT01081496 ·Status: COMPLETED
-
Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas
NCT01380795 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Evaluate EGFR Mutation Status and Impact Factors in North China
NCT02620657 ·Status: COMPLETED
-
NGS Genome Analysis in Personalisation of Lung Cancer Treatment
NCT02281214 ·Status: COMPLETED ·Phase: NA
-
An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors
NCT02616211 ·Status: COMPLETED
-
Comparison of Sequencing and PNA Clamping of EGFR Gene in Patients With Non-Small Cell Type Lung Cancer
NCT01767974 ·Status: UNKNOWN
-
EGFR Mutation Detection From Advanced NSCLC Patient Tissue and Plasma in EGFR-TKI Treatment
NCT02644889 ·Status: UNKNOWN
-
Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC
NCT01775943 ·Status: UNKNOWN
-
Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients
NCT04912687 ·Status: COMPLETED ·Phase: NA
-
Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression
NCT02431169 ·Status: TERMINATED
-
Observational Study to Characterize the Incidence of EGFR Mutation Positive and Advanced NSCLC Patients
NCT01717105 ·Status: UNKNOWN
-
K-RAS and EGFR in Lung Cancer
NCT03951233 ·Status: COMPLETED
-
A Study of Prevalence of EGFR Mutations in Participants With NSCLC
NCT02695849 ·Status: COMPLETED
-
Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection
NCT00831454 ·Status: COMPLETED
-
Detection of EGFR Mutations in the Blood of Patients With Non-small Cell Lung Cancer: a Feasibility Study
NCT00717002 ·Status: COMPLETED
-
Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA
NCT02629523 ·Status: COMPLETED ·Phase: PHASE2
-
Development of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung Cancer
NCT00897533 ·Status: COMPLETED
-
De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
NCT01697163 ·Status: UNKNOWN
-
Epidermal Growth Factor Receptor Mutations in the Blood of Patients With Advanced Non-Small Cell Lung Cancer
NCT00899756 ·Status: COMPLETED